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14. Treatment repeated every 3 weeks until progression up to maximum 
six cycles. Primary end point was overall response rate and secondary 
end points were overall survival, time to progression and toxicity.
Results: Thirty seven patients with advanced NSCLC were enrolled. 
The median age of the patients was 60 years (range: 44 to 72). The per-
formance status (WHO) was 0 in 4, 1 in 30 and 2 in 3 patients. Twenty 
three patients completed six cycles. Complete response was achieved in 
1 (3%) patient, partial response in 22 (59%) patients, stable disease in 9 
(24%) patients. Overall response rate was 62% on intent to treat basis. 
Among patients who response evaluation was possible (33 patients), re-
sponse rate was 70%. The median survival time was 14.5 months (95% 
CI 6.9, 22.3) and the 1 year survival was 35% and then median time to 
progression was 3.4 months(95% CI 3, 3.9). Toxicities were moder-
ate and mostly hematological adverse events. Grade 3/4 neutropenia 
occurred in 37%, 5 patients with febrile neutropenia. Grade 3/4 anemia 
and thrombocypenia was occurred in 37% and 5%. Nonhematologic 
toxicities were mild. 
Conclusion: The combination therapy consisted of gemcitabine, cispla-
tin and UFT is active and well tolerable ﬁrst line regimen for NSCLC 
patients. 
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Background: Cisplatin-based adjuvant chemotherapy improves 
survival in completely resected NSCLC patients, in recent phase III 
trials, such as IALT, JBR10 and ANITA. This phase II trial assessed the 
efﬁcacy and safety proﬁles of bi-weekly schedule of carboplatin and 
paclitaxel as adjuvant chemotherapy.
Methods: Patients registered from July 2001 to October 2003. Eligibil-
ity criteria included: completely resected NSCLC (Stage IB, IIA/B, 
IIIA/B (pm1)), PS 0-1, age less than 80, no prior chemotherapy/ra-
diotherapy, adequate hematological, liver, renal functions, written 
informed consent. The patients received chemotherapy with paclitaxel 
90mg/m2 and carboplatin AUC3 every 2 weeks x6, within 8 weeks after 
surgery. As a short premedication, 8 mg of dexamethasone, 5mg of d-
chlorpheniramine maleate and 50mg of ranitidine were administered in-
travenously 30 minutes, before the patients receive paclitaxel. Primary 
endpoints were disease-free survival and adverse events. Secondary 
endpoint was compliance.
Results: Seventy-two patients were enrolled in this study. Of these, 5 
patients were considered ineligible; 4 patients were out of criteria and 1 
patient did not receive chemotherapy. Then, 67 patients were evaluable 
for disease-free survival and adverse events. Fifty patients (74.6%) 
completed all cycles of therapy, and the average number of cycles 
administered was 5.1. Enrolled patients consisted of 50 males and 17 
females, with median age 64 (range; 33-79). They included 41 adeno-
carcinomas, 21 squamous cell carcinomas, 3 large cell carcinoma and 2 
others. Twenty-four patients were in Stage IB, 16 in II, 21 in IIIA, 6 in 
IIIB. The hematologic adverse event was mild and consisted mostly of 
neutropenia, in 7 patients for grade 3, and 2 for grade 4. These events 
in grade 3/4 occurred 19% in less than 60 y/o, 8% in 60-69 y/o, and 
15% in more than 70 y/o. The non-hematologic adverse events were 
observed in 6 patients for grade 3, such as general fatigue, appetite loss, 
constipation, diarrhea, colitis, peripheral nerve disorder, arthralgia. 
The median follow-up period was 1102 days (141-1674 days). The 
frequency of recurrent-disease was 26.9% (IB 16%, IIA 0%, IIB 23%, 
IIIA 40%, and IIIB 50%). The 4-year disease-free survival and overall 
survival rates of 67 patients were 72.4% and 77.9% respectively. The 
4-year disease-free survival of patients with IB-II was 82.1% and that 
of patients with III-IV were 57.8%. The 4-year overall survival rate in 
stage IB-II and III-IV were 85.4% and 67.7%, respectively.
Conclusions: Bi-weekly schedule of carboplatin and paclitaxel as ad-
juvant chemotherapy was well tolerated in completely resected NSCLC 
patients, also in elderly patients. The results of our trial suggest favor-
able outcome in both disease-free and overall survivals, therefore, it 
seem to be a candidate arm of further trial.
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Background: Although doublet chemotherapy is a standard treat-
ment regimen for PS 0-1 patients with advanced NSCLC, the optimal 
chemotherapy for previously untreated PS 2 patients with advanced 
NSCLC still remains to be established. We conducted a randomized 
phase II study to compare the efﬁcacy and safety of a platinum-doublet 
regimen (CP) versus a non-platinum doublet regimen (GV) in PS 2 
patients with advanced NSCLC. 
Patients and Methods: Chemotherapy-naive patients with stage IIIB 
(malignant effusion) and IV NSCLC were eligible for this study. All pa-
tients were required ECOG PS 2. The patients were randomly assigned 
to carboplatin area under the curve of 6 plus paclitaxel 200 mg/m2 on 
day 1 every 3 weeks (the CP arm) or gemcitabine 1000 mg/m2 plus 
vinorelbine 25 mg/m2 on days 1 and 8 every 3 weeks (the GV arm). 
The primary endpoint was 1-year survival rate while the secondary 
endpoints were response rate, time to progression, toxicity, and quality 
of life (QOL). The sample size was 41 assessable patients in each arm.
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Results: Of the 89 patients enrolled, 84 were assessable for efﬁcacy 
and toxicity: 41 patients (median age 65 years, male/female 30/11, 
stage IIIB/IV 7/34) in the CP arm and 43 (median age 67 years, 
male/female 31/12, stage IIIB/IV 7/36) in the GV arm. The 1-year 
survival rates and the median survival time were 22.0% (95% CI, 9.3 
to 34.6%) and 5.9 months for the CP arm, and 27.9% (95% CI, 14.5 
to 41.3%) and 6.0 months for the GV arm, respectively. On the other 
hand, the overall response rate and the time to progression were 29.3% 
(95% CI, 16.1 to 45.5%) and 2.9 months for the CP and 20.9% (95% 
CI, 9.3 to 34.6%) and 2.6 months for the GV arm, respectively. The 
selected grade 3/4 toxicity in the CP and GV arms included neutropenia 
(67.5% vs 65.1%, respectively), anemia (12.5% vs 30.2%), throm-
bocytopenia (7.5% vs 11.6%), febrile neutropenia (17.1% vs 11.6%), 
pneumonitis (4.9% vs 11.6%), liver dysfunction (2.5% vs 9.3%), and 
neuropathy (4.9% vs 0%). One treatment-related death occurred in the 
CP compared with three in the GV arm.The QOL improved after each 
treatment and it was similar between the two arms.
Conclusions: Both CP and GV arms appear to be active in PS 2 
patients with advanced NSCLC with 1-year survival rates of more than 
20% and median survival times of approximately 6 months. Although 
the toxicity proﬁles were different between the two arms, the GV arm 
caused more treatment-related deaths.
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Backgrounds: There are only a few reports about third and fourth line 
chemotherapy for advanced non-small cell lung cancer (NSCLC). The 
efﬁcacy of salvage chemotherapy has not been demonstrated yet. We 
conducted a retrospective study to investigate the efﬁcacy of third and 
fourth line chemotherapy.
Patients and Methods: This study was retrospective study of salvage 
chemotherapy. Patients diagnosed with advanced NSCLC or recurred 
after the curative resection in Kanazawa University Hospital and 
received more than one regimen chemotherapy were enrolled to this 
study. Patients received adjuvant chemotherapy after the curative resec-
tion was excluded. Response was evaluated using RECIST guidelines. 
Survival was estimated by the Kaplan-Meier method.
Results: Consecutive 82 patients were treated from January 2002 to 
March 2005. Median age of all patients was 62 (33-88), male was 51 
and female was 31. Histology included adenocarcinoma 62 (76%), 
squamous cell carcinoma 12 (14%), large cell carcinoma 4 (5%), and 
other 4 (5%). Response rate of ﬁrst line chemotherapy was 19.2% (15 
of 82). Overall survival of 82 patients was 352 days. 36 of 82 patients 
(44%) received more than three regimens of chemotherapy. Median age 
of 36 patients was 60 year old (40-81), male/female; 23/13. Histologi-
cal subtype were adenocarcinoma 32 (76%), squamous cell carcinoma 
5 (12%), large cell carcinoma 3 (7%), and other 2 (5%). Performance 
status 0-1 was 30 (83.3%). Most of chemotherapy from third line was 
geﬁtinib or single agent of third generation chemotherapeutic drug, and 
platinum based regimens were administered in 3 cases in third line and 
2 cases in fourth line. Response rate in third and fourth line chemother-
apy were 13.8% (4 of 36, geﬁtinib in 3 cases and irinotecan in 1case) 
and 14.3% (2 of 16, geﬁtnib + paclitaxel and cisplatin + gemcitabne), 
respectively. There is no objective response by ﬁﬁth chemotherapy 
regimen. Median survival from third line chemotherapy was 204 days.
Conclusions: Response rate in third and fourth line chemotherapy 
was more than 10%. Prospective study to prove the efﬁcacy of salvage 
chemotherapy is needed because of lack of evidence for salvage che-
motherapy.
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Background: Platinum-based doublet chemotherapy is generally 
accepted as standard therapy in advanced NSCLC patients. However, 
symptomatic beneﬁt under the serial chemotherapy is rarely evaluated 
in the phase II settings. The objectives of this study were to evaluate ef-
ﬁcacy, toxicity, and quality-of-life (QOL) status in such patients treated 
with CV.
Methods: Pathologically proven advanced NSCLC patients of age un-
der 70 with good performance status (PS) were eligible. The treatment 
consisted of carboplatin (AUC = 5.0) as a 1-hour infusion on day 1, and 
vinorelbine (25 mg/m2) as a 10-minute infusion on days 1 and 8, re-
peated every 21 days, according to the results of our phase I study. The 
Response Evaluation Criteria In Solid Tumor guideline was used for 
assessing efﬁcacy, Commom Terminology Critera for Adverse Events 
v3.0 for toxicity, and EORTC QLQ-C30 / LC13 for QOL.
Results: Thirty-ﬁve patients with mean age of 59.5 years were en-
rolled. Twenty-ﬁve were male, and 10 were female. Thirty-one patients 
were stage IV disease, and 29 / 5 / 1 patients had adenocarcinoma / 
squamous cell carcinoma / adenosquamous cell carcinoma, respective-
ly. Total number of delivered courses was 116, with an average of 3.3 
courses per patient. Treatment schedule was delayed in 29 courses, and 
the treatment dose was reduced in 9 courses. Overall response rate was 
37.1% with 13 partial-response patients. Median survival time was 391 
days, and median duration of response was 118 days. Grade 3 / 4 leuko-
penia, neutropenia, and anemia were observed in 19 / 7, 7 / 24, and 8 / 
0 patients. Two grade 3 febrile neutropenia patients were also reported. 
QLQ-C30 results showed almost no difference from the baseline in 
global health status / QOL and functional scales after treatment, but 
signiﬁcant pain reduction and dyspnea worsening in symptom scales / 
items. QLQ-LC13 also resulted in signiﬁcant reduction of cough, pain, 
and dysphagia, with signiﬁcant worsening of hair loss and dyspnea. 
Worsening of dyspnea seemed to be associated with anemia progres-
sion during the treatment.
Conclusions: The CV combination is well tolerated with comparable 
activity in advanced NSCLC patients, and QOL assessment revealed 
symptomatic efﬁcacy of this treatment. Because of the low non-hema-
tological toxicity proﬁle, this combination may be suitable for treating 
elderly and / or unﬁt patients. In this regard, we are now on the investi-
